The test can accurately identify mutations even when plasma samples are used as the specimen. Credit: OsloMetX from Pixabay.

Gencurix has received approval from the Korean Ministry of Food and Drug Safety for its companion diagnostic Droplex EGFR Mutation Test v2.

Designed to be used with Bio-Rad’s Droplet Digital PCR instrument, the test can identify EGFR mutations generally observed in non-small cell lung cancer (NSCLC) patients.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The IVD test will help select suitable targeted anticancer therapies based on the results. Last year, the company also secured CE certification for the test in Europe.

With a capacity to detect up to 107 mutations, the test can precisely identify mutations even when plasma samples are used as the specimen.

Furthermore, the test has the potential to identify Exon 20 Insertion mutation, which grabbed more attention in the oncologist community after the launches of Takeda’s Exkivity and Janssen’s Rybrevan.

According to the company, this test shows significantly higher sensitivity compared to existing EGFR mutation tests that use RT-PCR.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Gencurix strategy and business development vice-president Hyun Park said: “Gencurix has been developing diagnostic products that utilise Droplet Digital PCR technology, which has primarily been used for research purposes, in the field of cancer diagnostics.”

The company supplies diagnostic kits to Korean hospitals, including Yonsei Severance Hospital and Samsung Medical Center.

It is also focused on the development of solutions for early cancer detection and minimal residual disease screening using digital PCR technology.

Last April, the company launched a new technology for the detection of colorectal cancer recurrence.

In addition, the company has European CE registration for nine products, including C-MET, PIK3CA, ESR1, POLE and KRAS tests.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact